Glycosorb® ABO for living donor kidney transplants
More transplants mean a higher quality of life for patients and lower costs for society
Kidney disease is a major global and growing problem. In the US alone, there are 37 million people with chronic kidney problems and 500,000 people need dialysis three times a week. The situation is similar in most countries in the world. Continuous dialysis treatment is associated with various medical risks as well as significant negative social and psychological effects resulting from the patient being dependent of dialysis several times a week. At the same time, continuous dialysis means high costs for healthcare systems worldwide.
Kidney transplants dramatically improve quality of life
Since Glycosorb® ABO enables transplantation across the blood group barrier, more patients can get a new kidney and thereby shortening the general waiting times. Shorter waiting times are important from a medical point of view because the result of a kidney transplant improves the shorter the time the patient has been treated with dialysis before transplantation. A transplant generally means a longer life expectancy and a significant improvement in the patient’s quality of life by avoiding continuous, lifelong dialysis treatment. Patients can often return to work and a largely normal life after transplantation. In general, kidney transplantation from related living donors gives a clearly better result than transplantation from deceased donors.
Documented health economic effects
Since the first transplant in 2001, more than 6,000 transplants have been performed using Glycorex technology and the medical results have been presented in over 60 articles in reputable medical journals. Glycorex technology not only saves lives and improves patients’ quality of life, it also has very positive health economic effects. Each kidney transplant saves about 150 dialysis treatments per year. This means that the kidney transplants carried out after Glycosorb® ABO treatments, can be estimated to save over 900,000 dialysis treatments per year. With a dialysis population estimated today to be over two million worldwide and estimated to increase to over five million by 2030, there is a great need for more transplants also from a health economic point of view.
Clinical experience from more than 6,000 transplants with Glycosorb® ABO shows excellent long-term results
More than 6,000 patients in more than 25 countries have undergone blood group incompatible transplants using Glycosorb® ABO. Clinical experience shows that the results of the transplants have also been excellent over a longer follow-up period and are equivalent to the results of blood group compatible transplants.
Glycosorb® ABO is a safe treatment with few side effects
A unique advantage of Glycosorb® ABO is its very limited affect on other antibodies or blood proteins in the blood. This makes Glycosorb® ABO a unique product on the medical device market and means that any side effects are few and very mild. Studies show that the short-term and long-term results are excellent.